Clinical, functional and molecular characteristics of anemia with comorbid chronic obstructive pulmonary disease

The aim was to investigate an impact of different COPD phenotypes on clinical course of anemic syndrome.

Methods. This was a single-center prospective observational cohort study. Patients with stable COPD and anemia were involved (n = 215). COPD was diagnosed according to GOLD criteria and anemia was diagnosed according to WHO criteria. The control group included 90 healthy subjects. COPD patients with anemia were stratified according to pathogenic variants of anemia and serum erythropoietin level. COPD symptoms, exacerbations, lung function, pulmonary hemodynamics, the type of airway inflammation, hematology parameters, serum erythropoietin, hepcidin 25, vitamin B12, folate, and iron homeostasis were assessed. Statistical analysis was performed using SPSS 24 software. The groups were compared using chi square test for nominal variables and Kruskal-Wallis test for continuous variables. Logistic regression was used to explore the relationships between variables. Results. Anemia was diagnosed in 63 (29.3%) of patients including common pathogenetic variants of anemia in 12 (19.0 %) of patients: iron deficiency 9 (14.3%) and vitamin B12 deficiency 3 (4.8%). This anemia variants were associated with shorter duration of respiratory symptoms and was not related to COPD phenotype. The clinical course of anemia was modified due to comorbid COPD in 51 (81.0%) of patients. Anemia with normal / high erythropoietin level was found in 31 (49.2%) of COPD patients and was hypochromic, microcytic and hyperregeneratory. Those patients had low serum levels of iron, vitamin B12, and folate, low total and latent iron-binding capacity of serum, and high levels of ferritin and hepcidine. This type of anemia was associated with frequent COPD exacerbations. Anemia with low erythropoietin level 20 (31.7%) was normochromic, normocytic, and normoregeneratory, with normal serum iron and ferritin levels, low iron-binding capacity of serum, and low hepcidine level. This type of anemia was associated with combined pulmonary fibrosis and emphysema and with pulmonary hypertension. Conclusion. Anemic syndrome in COPD patients is associated with COPD phenotype.

1. Chetty U., McLean G., Morrison D. et al. Chronic obstructive pulmonary disease and comorbidities: a large cross-sectional study in primary care. Br. J. Gen. Pract. 2017; 67 (658): 321–328. DOI: 10.3399/bjgp17X690605.

2. Miller J., Edwards L.D., Agustí A. et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir. Med. 2013; 107 (9): 1376–1384. DOI: 10.1016/j.rmed.2013.05.001.

3. GOLD 2018. Global Strategy for the Diagnosis, Management and Prevention of COPD. Available at: http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf/ [Accessed 23 March, 2018].

4. Aisanov Z.R., Avdeev S.N., Arkhipov V.V. et al. National Guidelines on Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease an Algorithm for Making a Clinical Decision. Pul’monologiya. 2017; 27 (1): 13–20. DOI: 10.18093/0869-0189-2017-27-1-13-20 (in Russian).

5. Avdeev S.N. Chronic obstructive pulmonary disease as a systemic disorder. Pul’monologiya. 2007; (2): 104–117 (in Russian).

6. Barnes P.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2016;138 (1): 16–27. DOI: 10.1016/j.jaci.2016.05.011.

7. Suchdev P.S., Williams A.M., Mei Z. et al. Assessment of iron status in settings of inflammation: challenges and potential approaches. Am. J. Clin. Nutr. 2017; 106 (Suppl. 6): 1626–1633. DOI: 10.3945/ajcn.117.155937.

8. Tandara L., Grubisic T.Z., Ivan G. et al. Systemic inflammation up-regulates serum hepcidin in exacerbations and stabile chronic obstructive pulmonary disease. Clin. Biochem. 2015; 48 (18): 1252–1257. DOI: 10.1016/j.clinbiochem.2015.07.010.

9. Robalo Nunes A., Tátá M. The impact of anaemia and iron deficiency in chronic obstructive pulmonary disease: A clinical overview. Rev. Port. Pneumol. 2017; 23 (3): 146–155. DOI: 10.1016/j.rppnen.2016.12.005.

10. Cluzeau T., McGraw K.L., Irvine B. et al. Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes. Haematologica. 2017; 102 (12): 2015–2020. DOI: 10.3324/haematol.2016.158857.

11. Sharma R.K., Chakrabarti S. Anaemia secondary to erythropoietin resistance: important predictor of adverse outcomes in chronic obstructive pulmonary disease. Postgrad. Med. J. 2016; 1093 (92): 636–640. DOI: 10.1136/postgradmedj-2015-133814.

12. Comeche Casanova L., Echave-Sustaeta J.M., García Luján R. et al. Prevalence of anaemia associated with chronic obstructive pulmonary disease. Study of associated variables. Arch. Bronconeumol. 2013; 49 (9): 383–387. DOI: 10.1016/j.arbres.2013.04.007.

13. Markoulaki D., Kostikas K., Papatheodorou G. et al. Hemoglobin, erythropoietin and systemic inflammation in exacerbations of chronic obstructive pulmonary disease. Eur. J. Intern. Med. 2011; 22 (1): 103–107. DOI: 10.1016/j.ejim.2010.07.010.

14. Horadagoda C., Dinihan T., Roberts M. et al. Body composition and micronutrient deficiencies in patients with an acute exacerbation of chronic obstructive pulmonary disease. Intern. Med. J. 2017; 47 (9): 1057–1063. DOI: 10.1111/imj.13453.

15. Fimognari F.L., Loffredo L., Di Simone S. et al. Hyperhomocysteinaemia and poor vitamin B status in chronic obstructive pulmonary disease. Nutr. Metab. Cardiovasc. Dis. 2009; 19 (9): 654–659. DOI: 10.1016/j.numecd.2008.12.006.

16. Cote C., Zilberberg M.D., Mody S.H. et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur. Respir. J. 2007; 29 (5): 923–929. DOI: 10.1183/09031936.00137106.

17. Boutou A.K., Stanopoulos I., Pitsiou G.G. et al. Anemia of chronic disease in chronic obstructive pulmonary disease: a case-control study of cardiopulmonary exercise responses. Respiration. 2011; 82 (3): 237–245. DOI: 10.1159/000326899.

18. Kuzubova N., Privalova E., Titova O., et al. Secondary erythrocytosis and anemia in chronic obstructive pulmonary disease. Vrach. 2013; (2): 29–31 (in Russian).

19. Gadre S.K., Jhand A.S., Abuqayyas S. et al. Effect of anemia on mortality in mechanically ventilated patients with chronic obstructive pulmonary disease. J. Intensive Care Med. 2017; 885066617739561. DOI: 10.1177/0885066617739561.

20. Akramova E.G., Struchkov P.V. An impact of anemia on cardiovascular functional status in patients with chronic obstructive pulmonary disease. Pul’monologiya. 2012; (5): 28–32. DOI: 10.18093/0869-0189-2012-0-5-28-32 (in Russian).

21. Ferrari M., Manea L., Anton K. et al. Anemia and hemoglobin serum levels are associated with exercise capacity and quality of life in chronic obstructive pulmonary disease. BMC Pulm. Med. 2015; 15: 58. DOI: 10.1186/s12890-015-0050-y.

22. Budnevskiy A.V., Provotorov V.M., Ul’yanova M.I. Chronic obstructive pulmonary disease and anemia: manifestations and therapeutic approach. Klinicheskaya meditsina. 2016; 94 (9): 677–683. Available at: https://cyberleninka.ru/article/v/hronicheskaya-obstruktivnaya-bolezn-legkih-i-anemiya-klinicheskie-proyavleniya-i-taktika-lecheniya (in Russian).

23. Oh Y.M., Park J.H., Kim E.K. et al. Anemia as a clinical marker of stable chronic obstructive pulmonary disease in the Korean obstructive lung disease cohort. J. Thorac. Dis. 2017; 9 (12): 5008–5016. DOI: 10.21037/jtd.2017.10.140.

24. Lau C.S., Siracuse B.L., Chamberlain R.S. Readmission after COPD exacerbation scale: determining 30-day readmission risk for COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 1891–1902. DOI: 10.2147/COPD.S136768.

25. Cazzola M., Calzetta L., Rogliani P. et al. The challenges of precision medicine in COPD. Mol. Diagn. Ther. 2017; 21 (4): 345–355. DOI: 10.1007/s40291-017-0266-z.

26. Chuchalin A.G., Aisanov Z.R., Chikina S.Yu., et al. Federal Clinical Guidelines of Russian Respiratory Society on Spirometry. Pul'monologiya. 2014; (6): 11–24. DOI: 10.18093/0869-0189-2014-0-6-11-24 (in Russian).

27. Agustí A., Edwards L.D., Rennard S.I. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012; 7 (5): e37483. DOI: 10.1371/journal.pone.0037483.

28. Olenscki Gilli S.C., Pericole F.V., Benites B.D. et al. Cytokine polymorphisms in sickle cell disease and the relationship with cytokine expression. Exp. Hematol. 2016; 44 (7): 583–589. DOI: 10.1016/j.exphem.2016.03.008.

29. Platzbecker U., Germing U., Götze K.S. et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicenter a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017; 18 (10): 1338–1347. DOI: 10.1016/S1470-2045(17)30615-0